@article{fc62a97abaf64382bc1b3e083e703917,
title = "Ad26.COV2.S and SARS-CoV-2 spike protein ferritin nanoparticle vaccine protect against SARS-CoV-2 Omicron BA.5 challenge in macaques",
abstract = "Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines demonstrate reduced protection against acquisition of BA.5 subvariant but are still effective against severe disease. However, immune correlates of protection against BA.5 remain unknown. We report the immunogenicity and protective efficacy of vaccine regimens consisting of the vector-based Ad26.COV2.S vaccine and the adjuvanted spike ferritin nanoparticle (SpFN) vaccine against a high-dose, mismatched Omicron BA.5 challenge in macaques. The SpFNx3 and Ad26 + SpFNx2 regimens elicit higher antibody responses than Ad26x3, whereas the Ad26 + SpFNx2 and Ad26x3 regimens induce higher CD8 T cell responses than SpFNx3. The Ad26 + SpFNx2 regimen elicits the highest CD4 T cell responses. All three regimens suppress peak and day 4 viral loads in the respiratory tract, which correlate with both humoral and cellular immune responses. This study demonstrates that both homologous and heterologous regimens involving Ad26.COV2.S and SpFN vaccines provide robust protection against a mismatched BA.5 challenge in macaques.",
keywords = "B cell, BA.5, Omicron, SARS-CoV-2, T cell, antibody, macaque, vaccine",
author = "Jingyou Yu and Thomas, {Paul V.} and Michaela Sciacca and Cindy Wu and Jinyan Liu and Xuan He and Jessica Miller and Hachmann, {Nicole P.} and Nehalee Surve and Katherine McMahan and Catherine Jacob-Dolan and Olivia Powers and Kevin Hall and Julia Barrett and David Hope and Mazurek, {Camille R.} and Tetyana Murdza and Chang, {William C.} and Emily Golub and Rees, {Phyllis A.} and Peterson, {Caroline E.} and Agnes Hajduczki and Chen, {Wei Hung} and Martinez, {Elizabeth J.} and Elizabeth Hussin and Camille Lange and Hua Gong and Matyas, {Gary R.} and Mangala Rao and Mehul Suthar and Mona Boursiquot and Anthony Cook and Laurent Pessaint and Lewis, {Mark G.} and Hanne Andersen and Bolton, {Diane L.} and Michael, {Nelson L.} and Joyce, {M. Gordon} and Kayvon Modjarrad and Barouch, {Dan H.}",
note = "Funding Information: We thank Holly Thomasson, Katelyn Steingrebe, and Elyse Teow for animal procedures. We thank Jake Yalley-Ogunro, Mehtap Cabus, and Tim Moran for preparations of immunogens and processing. This work was partially executed through a cooperative agreement between the US Department of Defense and the Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. ( W81XWH-18-2-0040 ). Research was conducted under an approved animal use protocol in an AAALAC International-accredited facility in compliance with the Animal Welfare Act and other federal statutes and regulations relating to animals and experiments involving animals and adheres to principles stated in the Guide for the Care and Use of Laboratory Animals, NRC Publication, 2011 edition. The views expressed are those of the authors and should not be construed to represent the positions of the US Army, the Department of Defense, or the Henry M. Jackson Foundation (HJF). We further acknowledge support from National Institutes of Health grant CA260476 , the Massachusetts Consortium for Pathogen Readiness , and the Ragon Institute (DHB). Funding Information: We thank Holly Thomasson, Katelyn Steingrebe, and Elyse Teow for animal procedures. We thank Jake Yalley-Ogunro, Mehtap Cabus, and Tim Moran for preparations of immunogens and processing. This work was partially executed through a cooperative agreement between the US Department of Defense and the Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. (W81XWH-18-2-0040). Research was conducted under an approved animal use protocol in an AAALAC International-accredited facility in compliance with the Animal Welfare Act and other federal statutes and regulations relating to animals and experiments involving animals and adheres to principles stated in the Guide for the Care and Use of Laboratory Animals, NRC Publication, 2011 edition. The views expressed are those of the authors and should not be construed to represent the positions of the US Army, the Department of Defense, or the Henry M. Jackson Foundation (HJF). We further acknowledge support from National Institutes of Health grant CA260476, the Massachusetts Consortium for Pathogen Readiness, and the Ragon Institute (DHB). D.H.B. and J.Y. designed the study and reviewed all data. P.V.T. W.C.C. E.G. P.A.R. C.E.P. A.H. W.-H.C. E.J.M. N.L.M. M.G.J. and K.M. provided the SpFN immunogen; E.H. C.L. H.G. G.R.M. and M.R. provided the ALFQ adjuvant; M. Sciacca, C.W. J.L. X.H. J.M. N.P.H. N.S. K.M. C.J.-D. O.P. K.H. J.B. D.H. C.R.H. and T.M. performed the immunologic and virologic assays; M.G.L. and H.A. led the animal work with the involvement of D.L.B. N.L.M. and K.M.; M. Suthar provided the SARS-CoV-2 BA.5 challenge stock. J.Y. and D.H.B. wrote the paper with the involvement of all co-authors. D.H.B. is a co-inventor on provisional vaccine patents licensed to Janssen (63/121,482; 63/133,969; 63/135,182) and serves as a consultant to Pfizer. M.G.J. and K.M. are co-inventors on international patent application WO/2021/178971 A1 entitled “Vaccines against SARS-CoV-2 and other coronaviruses.” M.G.J. is a co-inventor on international patent application WO/2018/081318 and a US patent 10,960,070 entitled “Pre-fusion coronavirus spike proteins and their use.” K.M.{\textquoteright}s current affiliation is Pfizer. Publisher Copyright: {\textcopyright} 2023 The Authors",
year = "2023",
month = apr,
day = "18",
doi = "10.1016/j.xcrm.2023.101018",
language = "English",
volume = "4",
journal = "Cell Reports Medicine",
issn = "2666-3791",
number = "4",
}